REG - Cambridge Cognition - Expansion in Chinese market
RNS Number : 6376ICambridge Cognition Holdings PLC12 August 2019
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Cambridge Cognition expands further into Chinese market
and initial university contract
Cambridge Cognition Holdings plc (AIM: COG), which delivers digital solutions for optimising cognitive assessment, is pleased to announce its expansion into the Chinese market with the Company's Cambridge Neuropsychological Test Automated Battery ("CANTAB") computerised assessments. This move strengthens the Company's global position, having announced a major opportunity in India earlier this year.
CANTAB are world-renowned assessments that accurately measure all areas of cognition. With over 2,200 peer-reviewed publications describing the use of CANTAB tests in both research and clinical trials, the Company believes CANTAB is the gold-standard in cognitive assessments. To make these available for the Chinese market, Cambridge Cognition have developed task variants in the key spoken (Cantonese and Mandarin) and written (Chinese simplified) languages.
To support Chinese companies and global studies collecting data in China, Cambridge Cognition is establishing a secure cloud infrastructure, using Amazon Web Services, in a data centre in China to enable straight-forward compliance with China's scientific data transfer regulations.
On the strength of these developments, Cambridge Cognition has already signed a recurring annual contract with Fudan University, Shanghai, which is ranked in the top 5 Chinese universities.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
"By establishing a cloud infrastructure in a data centre in China and translating tasks into the key languages, we have brought CANTAB to the Chinese market in a way that considerably expands our commercial opportunities. This a major step forward for Cambridge Cognition's global expansion plans. Many of our CANTAB tasks are now available in almost 50 languages and have been used worldwide in over 100 countries."
For further information, contact:
Cambridge Cognition Holdings PLC
Matthew Stork, Chief Executive Officer
Nick Walters, Chief Financial Officer
Tel: 012 2381 0700
finnCap Ltd (NOMAD and Joint Broker)
Geoff Nash / Simon Hicks
Alice Lane / Manasa Patil
Tel: 020 7220 0500
(Corporate Finance)
(Corporate Broking)
Dowgate Capital Limited (Joint Broker)
David Poutney / James Serjeant
Tel: 020 3903 7715
IFC Advisory Ltd (Financial PR and IR)
Tim Metcalfe / Miles Nolan / Zach Cohen
Tel: 020 3934 6630
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDMSCBIGDIIXBBGCB
Recent news on Cambridge Cognition Holdings
See all newsREG - Cambridge Cognition - Preliminary Results, Trading Update & Board Change
AnnouncementREG - Cambridge Cognition - Notice of Results
AnnouncementREG - Cambridge Cognition - COG spin-out Monument Therapeutics accesses £1.5m
AnnouncementREG - Cambridge Cognition - Total Voting Rights and Block Listing Return
AnnouncementREG - Cambridge Cognition - Formation of new Scientific Advisory Board
Announcement